All In Biotech

Drug Trial Radar · NCT02720783

Tolerability and Pharmacokinetic Study of Econazole Nitrate Plus Benzydamine HCl Vaginal Pessary

A Phase I Study of a Novel Antimycotic Vaginal Pessary Formulation (Econazole Nitrate 150 mg + Benzydamine HCl 6 mg) Administered Once Daily for 3 Days to Healthy Women

Last checked: Nov 19, 2026Latest source record: Feb 7, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

49

Actual

Start

Mar 4, 2016

Primary completion

Oct 12, 2016

Study completion Oct 12, 2016

Sponsor

Sponsor type
Industry
Collaborators
Cross Research S.A.
First posted
Mar 28, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Other
Who can join
Female only, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The primary objective of the study is to evaluate the local tolerability of the new Econazole/Benzydamine pessary, in comparison with Econazole and Benzydamine stand-alone products and placebo. Pharmacokinetics of the study products after single and multiple applications o.d. for 3 days, overall local and general tolerability, safety and comfort of use will also be evaluated.

Conditions

  • Healthy Women

Interventions

  • Econazole nitrate 150 mg plus Benzydamine HCl 6 mg vaginal pessaryDrug

    Econazole nitrate 150 mg plus Benzydamine HCl 6 mg vaginal pessary

  • Placebo plus Econazole nitrate 150 mg vaginal pessaryDrug

  • Placebo plus Benzydamine HCl 6 mg vaginal pessaryDrug

  • Placebo vaginal pessaryDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Local Adverse Drug Reactions (ADRs)Time frame: Up to 7 days after administration

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • CROSS Research S.A., Phase I Unit

    Arzo, Switzerland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.